Skip to main content
Fig. 4 | BMC Neurology

Fig. 4

From: Real-World Safety and Efficacy of 156 U – 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study

Fig. 4

Evaluation of onabotulinumtoxinA treatment tolerability. Evaluation of onabotulinumtoxinA treatment tolerability. Patient (a-b) Physician (c-d) evaluation of tolerability (very good, good, moderate, or bad) at administration visit 1 through visit 8. Patients treated with 155 U onabotulinumtoxinA (left) or 156 – 195 U (right) at 4 or more visits. U, units

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us